DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models

por Yuki Kagoya, Munehide Nakatsugawa, Kayoko Saso, Tingxi Guo, Mark Anczurowski, Chung-Hsi Wang, Marcus O. Butler, Cheryl H. Arrowsmith, Naoto Hirano
Publicado 2018

HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway

por Yuki Yamashita, Mark Anczurowski, Munehide Nakatsugawa, Makito Tanaka, Yuki Kagoya, Ankit Sinha, Kenji Chamoto, Toshiki Ochi, Tingxi Guo, Kayoko Saso, Marcus O. Butler, Mark D. Minden, Thomas Kislinger, Naoto Hirano
Publicado 2017

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

por Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael Gordon, Leonel Hernandez-Aya, Donald Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy Mueller, Caroline Robert
Publicado 2020

Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

por Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael Gordon, Leonel Hernandez-Aya, Donald Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy Mueller, Caroline Robert
Publicado 2021

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity

por S. Y. Cindy Yang, Scott C. Lien, Ben X. Wang, Derek L. Clouthier, Youstina Hanna, Iulia Cirlan, Kelsey Zhu, Jeffrey P. Bruce, Samah El Ghamrasni, Marco A. J. Iafolla, Marc Oliva, Aaron R. Hansen, Anna Spreafico, Philippe L. Bedard, Stephanie Lheureux, Albiruni Razak, Vanessa Speers, Hal K. Berman, Alexey Aleshin, Benjamin Haibe-Kains, David G. Brooks, Tracy L. McGaha, Marcus O. Butler, Scott V. Bratman, Pamela S. Ohashi, Lillian L. Siu, Trevor J. Pugh
Publicado 2021

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

por Omid Hamid, Brendan Curti, Craig L Slingluff, Mohammed Milhem, Jose Lutzky, Suthee Rapisuwon, Brian Gastman, Takami Sato, Marcus O Butler, Robert Andtbacka, Eddy Hsueh, Robert Weber, John Glaspy, Sekwon Jang, Sajeve Thomas, Karl D Lewis, Leonel Hernandez-Aya, John Hyngstrom, Adam Berger, Edward Levine, Montaser F Shaheen, Vinay Gupta, Svetomir N Markovic, Tawnya Bowles, Joel Claveau, Prejesh Philips, Shernan G Holtan, William Schmidt, Juan Paramo, Arvinda Padmanabhan, Daniel Milton, Andrew Pecora, Suprith Badarinath, John Keech, Sujith Kalmadi, Pallavi Kumar, Anna Bar, J Thaddeus Beck, Jeffrey B Travers, Catalin Mihalcioiu, Peter Beitsch, Edward C McCarron, Deepti Behl, Brent Blumenstein, Joanna J Peterkin
Publicado 2021